Research Chemical Designation & Liability

Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.

Full Disclaimer
Archive Identifier

Pemvidutide

Metabolic & Weight Loss

Molecular Dossier

  • Rank Index: 67
  • Status: Phase 2 Clinical
  • What does this mean?
  • Molecular Structure: MW: ~4,200 Da | Class: Fatty acid-conjugated GLP-1R/GcgR peptide | Route: Weekly SC

About Pemvidutide

Pemvidutide (ALT-801) is a fatty acid-conjugated, long-acting dual agonist of GLP-1 and glucagon receptors developed by Altimmune, designed for once-weekly subcutaneous administration. Its 48-week Phase 2b MOMENTUM trial in adults with obesity (BMI ≥30) demonstrated approximately 15.6% body weight reduction at the 2.4 mg dose. Notably, the trial produced some of the strongest liver-fat reduction data in the GLP-1 class: 54% reduction in liver fat content as measured by MRI-PDFF, suggesting potent hepatic benefit from its more balanced GLP-1/glucagon ratio. Unlike semaglutide (which has ~300:1 GLP-1:glucagon receptor selectivity), pemvidutide maintains a near 1:1 potency ratio, providing thermogenic and hepatic lipolytic effects that complement central appetite suppression. Phase 3 MASH-specific trials are in planning. Weekly subcutaneous injection. Adverse events are predominantly gastrointestinal (nausea 30–40% in 2.4 mg cohort) and consistent with GLP-1 class. Cardiovascular outcomes data are not yet available. The compound has attracted significant hepatology interest given the MASH epidemic: current estimates suggest 1.5–6.5% of the global population has MASH, with limited FDA-approved treatment options. Pemvidutide's liver-targeting profile may fill a gap that pure GLP-1 agents do not adequately address.

Clinical Focus

GLP-1/Glucagon Dual Agonist — Liver Fat Reduction & Obesity

Archival Aliases

ALT-801

Frequently Asked Questions

Clinical Data Matrix

Parameter Clinical Value
Molecular Weight MW: ~4,200 Da | Class: Fatty acid-conjugated GLP-1R/GcgR peptide | Route: Weekly SC
Primary Pathway Metabolic & Weight Loss
Research Phase Phase 2 Clinical

Clinical Pros

  • Highly selective receptor modulation
  • Documented efficacy in Phase II trials
  • Minimal systemic cross-reactivity

Research Limitations

  • Limited long-term human data
  • Strict storage and reconstitution requirements
  • Potential for acute homeostatic feedback loops

Community Discussion

Share your questions and experiences with other researchers in the forum.

Discuss in Forum

Clinical Reference Nodes

[REF 1] pubmed.ncbi.nlm.nih.gov
[REF 2] clinicaltrials.gov
[REF 3] altimmune.com

Data Verified: 2026-04-22

Synergistic Matrix